MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

Rhea-AI Summary

MaxCyte, a leading commercial cell-engineering company, announced it will release its financial results for Q3 2022 after the U.S. market close on November 9, 2022. The company will host a conference call at 4:30 p.m. ET to discuss the results. MaxCyte's proprietary Flow Electroporation platform enables advanced cell-based research and therapeutic development, supporting the rapidly growing cell therapy market. The ExPERT platform is integral to their offerings, which includes various instruments and a comprehensive intellectual property portfolio.

Positive

• MaxCyte has a robust intellectual property portfolio supporting its innovative technologies.
• The ExPERT platform addresses the growing cell therapy market, enhancing market position.

Negative

• None.

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the third quarter of 2022 after the U.S. market close on Wednesday, November 9^th, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com

FAQ

When will MaxCyte release its Q3 2022 financial results?

MaxCyte will release its Q3 2022 financial results on November 9, 2022, after the U.S. market close.

What time is the MaxCyte conference call for Q3 earnings?

The conference call to discuss MaxCyte's Q3 earnings will be held at 4:30 p.m. ET on November 9, 2022.

What is the focus of MaxCyte's business?

MaxCyte focuses on cell-engineering technologies for innovative cell-based research and cell therapeutic development.

What technologies does MaxCyte utilize?

MaxCyte utilizes its proprietary Flow Electroporation technology and the ExPERT platform to support cell therapy advancements.